Literature DB >> 7463330

Pharmacokinetics of oral and intravenous fluorouracil in humans.

T A Phillips, A Howell, R J Grieve, P G Welling.   

Abstract

The pharmacokinetics of fluorouracil were examined after single 250-mg iv doses and 500-mg oral doses to female patients with breast cancer. In five patients who received intravenous fluorouracil, the mean peak plasma level of unchanged drug was 13.4 microgram/ml, the elimination half-life was 6.3 min, and the plasma clearance was 1410 ml/min. The last value is similar to the hepatic blood flow. In six patients who received oral fluorouracil, the mean peak value of unchanged drug in plasma, which occurred within 20 min of dosing, was 8.3 microgram/ml, and the fluorouracil elimination half-life was 7.2 min. The overall bioavailability of oral fluorouracil as unchanged drug was 28%, and the variation in plasma drug levels between individuals was similar following oral and intravenous doses. The data provide additional evidence of saturable hepatic metabolism of fluorouracil during the first pass.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7463330     DOI: 10.1002/jps.2600691220

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Fabrication and evaluation of electrospun collagen/poly(N-isopropyl acrylamide)/chitosan mat as blood-contacting biomaterials for drug delivery.

Authors:  Saravanabhavan Shanmuga Sundar; Dharmalingam Sangeetha
Journal:  J Mater Sci Mater Med       Date:  2012-04-03       Impact factor: 3.896

2.  Regional delivery of model compounds and 5-Fluorouracil to the liver by their application to the liver surface in rats: its implication for clinical use.

Authors:  Koyo Nishida; Rie Fujiwara; Yukinobu Kodama; Shintaro Fumoto; Takahiro Mukai; Mikiro Nakashima; Hitoshi Sasaki; Junzo Nakamura
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

3.  The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.

Authors:  V J Harvey; M L Slevin; M R Dilloway; P I Clark; A Johnston; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

4.  Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer.

Authors:  Alaa Eldeen B Yassin; Md Khalid Anwer; Hammam A Mowafy; Ibrahim M El-Bagory; Mohsen A Bayomi; Ibrahim A Alsarra
Journal:  Int J Med Sci       Date:  2010-11-22       Impact factor: 3.738

5.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

6.  In situ delivery of thermosensitive gel-mediated 5-fluorouracil microemulsion for the treatment of colorectal cancer.

Authors:  Lu-Lu Wang; Shuai Huang; Hui-Hui Guo; Yan-Xing Han; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Drug Des Devel Ther       Date:  2016-09-08       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.